Evidence map›Paper›PMID 42041758›Full record

ArticleBrain sciences2026

In Silico-Identified miR-16-5p and miR-32-5p as a Shared Molecular Signature of Primary Gliomas and Parkinson's Disease: Plasma Levels Are Increased Only in Glioma Patients.

Janusz Szyndler, Zofia Wicik, Anna Wierucka, Piotr Maciejak, Michał Sobstyl, Angelika Stapińska-Syniec, Piotr Glinka, Karol Piwowarski, Natalia Chmielewska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Janusz SzyndlerDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CePT, Medical University of Warsaw, Banacha 1B Street, 02-097 Warsaw, Poland.
Zofia WicikDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland.
Anna WieruckaFaculty of Medicine, Medical University of Warsaw, Zwirki and Wigury 61 Street, 02-097 Warsaw, Poland.
Piotr MaciejakDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland.
Michał SobstylDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, Sobieskiego 9 Street 02-957 Warsaw, Poland.
Angelika Stapińska-SyniecDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, Sobieskiego 9 Street 02-957 Warsaw, Poland.ORCID 0000-0001-7838-3011
Piotr GlinkaDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, Sobieskiego 9 Street 02-957 Warsaw, Poland.
Karol PiwowarskiDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, Sobieskiego 9 Street 02-957 Warsaw, Poland.
Natalia ChmielewskaDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland.

Funding

This study was funded by internal resources of the Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, and the Department of Experimental and Clinical Neuroscience, Insti none
6 · The paper itself

Abstract

objectivesIn this study, we explore the molecular basis of the literature-reported inverse association between brain neoplasms and neurodegenerative disorders, including Parkinson's disease (PD). As miRNAs are post-transcriptional regulators, we selected them as candidates underlying opposite processes of neurodegeneration and glioma development.

methodsWe used bioinformatic analyses for disease-gene extraction, miRNA target prediction, enrichment analyses, and miRNA ranking. We identified 953 shared genes between PD and glioblastoma (GBM) in DisGeNET, then prioritized miRNAs predicted to regulate the largest number of shared targets. Next, we collected peripheral blood from patients with PD (

resultsWe observed increased levels of miR-16-5p (

conclusionsAlthough these analyses highlight miR-16-5p and miR-32-5p as candidate biomarkers associated with glioma related pathways, the results did not provide evidence for the expected opposite regulation between PD and glioma. Future studies with a larger cohort of patients using high-throughput methods are needed to validate these findings and to elucidate the mechanisms driving neurodegeneration or excessive proliferation.

Indexed as

gliomasmiR-16-5pmiR-32-5pp53Parkinson’s disease

Identifiers

PMID42041758
PMCPMC13115420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.